#AS­CO22: Play­ing catch-up with Lumakras: Mi­rati touts CNS-spe­cif­ic ac­tiv­i­ty that an­a­lysts think pad the case for ap­proval

CHICA­GO — Mi­rati Ther­a­peu­tics is pulling out all the stops to beef up its case for ada­gra­sib, as the biotech could be 18 months be­hind Am­gen’s Lumakras to mar­ket if ap­proved by the FDA in De­cem­ber.

The biotech said its drug led to six ob­jec­tive in­tracra­nial re­spons­es in 19 evalu­able pa­tients with non-small cell lung can­cer who have ac­tive and un­treat­ed CNS metas­tases. That 32% fig­ure is sim­i­lar to the 33% in­tracra­nial ORR pre­vi­ous­ly re­port­ed in pa­tients who have been treat­ed for the CNS metas­tases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.